Royalty Pharma has been making waves in the stock market, with shares reaching a 52-week high and significant shares changing hands amongst several investment firms. Notably,
Shares of Royalty Pharma have been purchased by
Aberdeen Group and
Envestnet Asset Management, while portions of
Shares were sold by entities like
Illinois Municipal Retirement Fund and
Allianz Asset Management.
UBS has upgraded the stock to Buy due to its attractive growth profile, echoed by financial pundit
Jim Cramer who referred to the company as 'Terrific'. Investors are keenly observing Royalty Pharma's Q4 Earnings and fiscal performance as its dividend increases. However, shares were also being offloaded by insiders including
Marshall Urist and
Terrance Coyne. The market is also taking note of Royalty Pharma's aggressive strategies, such as completing a $2B Senior Notes offering and a $275M funding deal with
Denali, with the stock enjoying a
35% one-year gain, despite sales figures falling below analyst estimates.
Royalty Pharma Stocks News Analytics from Fri, 29 Aug 2025 07:00:00 GMT to Fri, 20 Feb 2026 21:14:44 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor 5
